RESEARCH ARTICLE

Effects of ethanol and ethanol metabolites on intrinsic function of mesenteric resistance arteries

Jonathan M. Eby1,2, Matthias Majetschak3,4*

1 Department of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States of America, 2 Alcohol Research Program (ARP), Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States of America, 3 Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America, 4 Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America

* majetschak@health.usf.edu

Abstract

Evidence suggests that ethanol-induced hypertension is associated with increased cardiovascular responsiveness to vasopressors in vivo and enhanced reactivity of isolated arteries to vasopressors ex vivo. The underlying mechanisms are not well understood and the contribution of ethanol metabolites to vascular effects induced by ethanol consumption are unclear. Mesenteric resistance arteries were harvested from Sprague-Dawley rats. Pressure myography was utilized to test effects of ethanol, acetaldehyde and phosphatidylethanol on myogenic tone and on vasoconstriction induced by phenylephrine, arginine vasopressin (aVP), endothelin-1 and KCl. Ethanol concentrations in the vessel bath decreased with a half-life of 25min; acetaldehyde and phosphatidylethanol concentrations remained constant. Pretreatment with ethanol dose-dependently increased the potency of phenylephrine to induce vasoconstriction 4-fold (p<0.01). These effects were comparable when arteries were pre-treated with a single dose of ethanol for 30min and when ethanol concentrations were kept constant during 30min and 60min of pretreatment. While ethanol also dose-dependently increased the potency of aVP to induce vasoconstriction 1.7-fold (p<0.05), it did not affect vasoconstriction induced by endothelin-1 or KCl. Acetaldehyde pre-treatment (30 min) dose-dependently increased the potency of phenylephrine to induce vasoconstriction 2.7-fold (p<0.01) but did not affect other vasoconstrictor responses. Phosphatidylethanol did not affect any vasoconstrictor responses. Ethanol and its metabolites did not affect myogenic tone. These data suggest that ethanol and acetaldehyde selectively sensitize intrinsic constrictor responses upon activation of vascular α1-adrenergic and/or vasopressin receptors at clinically relevant concentrations. Our findings support the concept that enhanced vasoreactivity to vasoactive hormones contributes to the development of hypertension induced by ethanol consumption. Ex vivo exposure of resistance arteries to ethanol and acetaldehyde resembles effects of chronic ethanol consumption on intrinsic vascular function, and thus could serve as test platform.
to evaluate interventions aimed to mitigate vascular effects associated with ethanol consumption.

Introduction
Cardiovascular diseases are major health problems world-wide, affecting over 85 million people in the US alone [1]. During the past century, associations between chronic ethanol consumption and various cardiovascular diseases, such as arterial hypertension, stroke or myocardial infarction, have been firmly established [1, 2]. The effects of alcohol consumption on the cardiovascular system are complex and appear to depend on the dose and mode of alcohol consumption [3, 4]. While epidemiological studies suggested a U- or J-shaped dose-effect relationship between alcohol consumption and cardiovascular disease, with low-to-moderate drinking being beneficial, more recent epidemiological methodologies question this association [4]. It is well accepted, however, that chronic moderate-to-heavy drinking has detrimental effects on cardiovascular health [2, 4]. Chronic moderate-to-heavy drinking induces arterial hypertension in humans and animals [2–14]. This association is of major importance as hypertension is the single most important risk factor for global burden of disease and significant percentages of hypertension can be attributed to ethanol consumption [2, 15, 16].

The effects of ethanol consumption on blood pressure regulation are thought to involve the central and autonomic nervous systems [17, 18]. Furthermore, several lines of evidence suggest that ethanol has direct effects on vascular function and that ethanol-induced hypertension is associated with increased cardiovascular responsiveness to vasopressors in vivo and enhanced reactivity of isolated arteries to vasopressors ex vivo [2, 6, 7, 12, 17–20]. The mechanisms by which ethanol consumption alters intrinsic vascular function, however, are not well understood. Furthermore, the contribution of ethanol metabolites to alterations in intrinsic vascular function induced by ethanol consumption are unclear. As multiple previous reports suggested that vasoconstrictor responses upon α₁-adrenergic receptor (AR) activation are sensitized after chronic alcohol consumption [2, 6, 7, 21, 22], we tested whether such effects are also detectable in resistance arteries upon ethanol exposure ex vivo. We observed that a short exposure of isolated mesenteric resistance arteries to clinically relevant concentrations of ethanol sensitizes intrinsic vasoconstrictor responses to the selective α₁-adrenergic receptor agonist phenylephrine (PE), thus providing a simple test platform that recapitulates vascular consequences of ethanol consumption. Utilizing this test platform for detailed dose-response experiments with ethanol and its metabolites acetaldehyde and phosphatidylethanol, we provide evidence that ethanol and acetaldehyde have direct effects on vascular function, and dose-dependently and selectively sensitize intrinsic vasoconstrictor responses of mesenteric resistance arteries upon activation of α₁-adrenergic- and/or arginine vasopressin receptors. Our findings provide new insights into pathophysiological consequences of ethanol and ethanol metabolite exposure on the vasculature, which are likely to contribute to the etiology of hypertension induced by ethanol consumption.

Materials and methods
Proteins and reagents
Ethanol, acetaldehyde, phenylephrine, arginine vasopressin, endothelin-1 and KCl were purchased from SigmaAldrich (St. Louis, MO). Phosphatidylethanol was purchased from Avanti Polar Lipids, Inc (Alabaster, AL).
Pressure myography

Pressure myography was performed as described in detail previously, with slight modifications [23–27]. Male Sprague-Dawley rats weighing 300-350g were obtained from Envigo (Huntingdon, United Kingdom). All procedures were performed according to National Institutes of Health Guidelines for Use of Laboratory Animals and approved by the Loyola University Chicago Institutional Animal Care and Use Committee. Rats were anesthetized with 3.5% isoflurane, the mesentery was excised and animals were euthanized by bilateral pneumothorax and cardiectomy. The mesentery was immediately placed in a solution containing 130 mM NaCl, 4.7 mM KCl, 1.18 mM KH₂PO₄, 1.17 mM MgSO₄, 14.9 mM NaHCO₃, 5.5 mM D-Glucose, 0.026 mM EDTA, 1.16 mM CaCl₂ aerated with 95% O₂, 5% CO₂ at 37°C (PSS). Third or 4th order mesenteric resistance arteries were dissected free from adipose and connective tissue prior to mounting onto two glass cannulae with United States Pharmacopeia (USP) scale 11–0 sutures (Rockville, MD). Vessels were perfused and superfused with PSS, then pressurized to 80 mmHg in a DMT 110P pressure myography system (DMT-USA, Ann Arbor, MI) for 5 minutes prior to starting each experiment. The vessel bath superfusion was continuously aerated with 95% O₂, 5% CO₂ throughout the experiment. Vessels were pretreated with ethanol or one of its metabolites for 30 minutes prior to the addition of increasing doses of PE, arginine vasopressin (aVP), endothelin-1, and KCl to the vessel bath. Changes of the outer diameter (o.d.) of the pressurized vessel were measured continuously throughout the experiment via digital video-edge detection.

To study the effects of ethanol and its metabolites on myogenic tone, arteries were pressurized to 80 mmHg and pre-incubated with ethanol and its metabolites for 30 min. The intraluminal pressure was then reduced to 0 mmHg and increased by 20 mmHg every 5 min. Changes in the outer diameter of the arteries were measured as described above.

Measurements of ethanol concentrations

Ethanol concentrations in the vessel bath were measured using an AM1 Alcohol Analyzer (Analox, Huntington Beach, CA) according to the manufacturer’s instructions.

Acetaldehyde assay

Acetaldehyde concentrations in the vessel bath were measured using the colorimetric EnzyChrom Acetaldehyde Assay kit (BioAssay Systems, Hayward, CA), which is based on aldehyde dehydrogenase catalyzed oxidation of acetaldehyde, in which the formed NADH reduces a fozmazan reagent. The intensity of the product color, measured at 565 nm, is directly proportional to the acetaldehyde concentration in the sample. Assays were performed as per manufacturer’s protocol.

Phosphatidylethanol enzyme linked immunosorbent assay

Phosphatidylethanol concentrations in the vessel bath were measured with a phosphatidylethanol ELISA (Echelon Biosciences, Salt Lake City, UT) according to the manufacturer’s protocol.

Data analyses

Data are expressed as mean ± standard error of the mean (SEM) from n independent experiments. Experiments were performed on different days using different animals. Data analyses were performed using the GraphPad-Prism 7 software. Data were analyzed by one-way analyses of variance (ANOVA) with Dunnett’s multiple comparison post-hoc test. Dose response
curves and half-life decay curves were analyzed using non-linear regression analyses. A two-tailed p < 0.05 was considered significant.

Results

To test for direct effects of ethanol on α₁-AR-mediated vasoconstriction, mesenteric resistance arteries were pre-incubated with ethanol for 30 min, followed by stimulation with increasing doses of the selective α₁-AR agonist PE. Because ethanol evaporates from the aerated vessel bath during the experiment, we monitored ethanol concentrations in 15 min intervals. Fig 1A shows the time course of ethanol concentrations in the vessel bath along with the vasoconstrictor effects of PE when ethanol was added at a starting concentration of 100 mM. Ethanol concentrations in the vessel bath decreased with a half-life of 24.86 min (95% confidence interval: 21.5–29.5 min, n = 3 (t = 0–90 min)– 8 (t = 0–60 min)) under our experimental conditions. Addition of ethanol alone to the vessel bath did not induce vasoconstriction. Fig 1B shows the PE-induced vasoconstrictor effects when mesenteric resistance arteries were pre-incubated in the vessel bath with various concentrations of ethanol. While a starting concentration of 17.4 mM ethanol in the vessel bath, which reflects the legal blood alcohol limit for the operation of a vehicle in the US, did not alter the vasoconstrictor responses to PE, pre-incubation of mesenteric resistance arteries with a starting vessel bath concentration of 50 mM and 100 mM ethanol resulted in a left-shift of the vasoconstrictor responses to PE (Fig 1B). While ethanol pre-exposure of the arteries did not significantly affect maximal constriction induced by PE or Hill-slopes of the dose-response curves, ethanol dose-dependently increased the potency of PE to induce vasoconstriction ~ 4-fold (Fig 1C; EC₅₀ (nM, mean ± SEM): 0 mM ethanol (vehicle) - 1114 ± 207; 17.4 mM ethanol 915 ± 166; 50 mM ethanol – 383 ± 51 (p = 0.003 vs. vehicle); 100 mM ethanol– 283 ± 56 (p = 0.001 vs. vehicle)). We then tested the effects of ethanol when ethanol concentrations were maintained constant during the experiment. As before, arteries were pre-exposed to ethanol for 30 min, followed by stimulation with PE. Ethanol concentrations were measured in 5 min intervals and maintained constant by adding ethanol to the vessel bath to account for evaporative losses (Fig 1D). The vasoconstrictor dose-responses to PE in arteries exposed to a constant concentration of 17.4 mM ethanol were indistinguishable from those in arteries not exposed to ethanol. In contrast, exposure to a constant concentration of 100 mM ethanol resulted in a left-shift of the dose response curves to PE (Fig 1E). The EC₅₀ concentration for the vasoconstrictor effects of PE in arteries pre-exposed to a constant concentration of 100 mM of ethanol was significantly reduced to 329 ± 54 nM, as compared with arteries not exposed to ethanol (Fig 1F; vehicle: 973 ± 101 nM, p = 0.0057). To assess whether a longer pre-exposure would affect the sensitizing effects of ethanol, we then extended the pre-incubation period to a constant ethanol concentration to 1 hour (Fig 1G and 1H). This, however, did not affect the dose-dependency of the sensitizing effects of ethanol on PE-induced vasoconstriction (EC₅₀ (nM, mean ± SEM)): vehicle– 1064 ± 113; 17.4 nM ethanol– 762 ± 134; 100 nM ethanol– 359 ± 88 (p = 0.0082 vs. vehicle)). Pre-exposure of arteries to constant ethanol concentrations for 30 min and 60 min did not significantly affect maximal constriction or Hill-slopes of the dose-response curves for PE. Furthermore, the EC₅₀ concentrations for the vasopressor effects of PE in arteries pre-exposed to evaporating concentrations of ethanol for 30 min, to constant concentrations of ethanol for 30 min and to constant concentrations of ethanol for 60 min were not significantly different for each ethanol concentration.

Next, we studied whether the ethanol metabolites acetaldehyde and phosphatidylethanol would influence PE-induced constriction of isolated arteries (Fig 2). We confirmed that vessel bath concentrations of both ethanol metabolites remained constant during the 30 min pre-incubation period and the subsequent period of stimulation with increasing doses of PE (Fig
2A and 2D). Addition of acetaldehyde or phosphatidylethanol alone to the vessel bath did not induce vasoconstriction. We observed that preincubation of arteries with acetaldehyde caused a left-shift of the dose-response curve for PE-induced vasoconstriction (Fig 2B). While
acetaldehyde did not affect maximal PE-induced constriction and Hill-slopes of the PE-dose response curves, it significantly increased the potency of PE to induce constriction of isolated arteries 2.7-fold (Fig 2C, EC$_{50}$ (nM, mean ± SEM)): vehicle – 977 ± 108; 5 μM acetaldehyde – 405 ± 42 (p = 0.0084 vs. vehicle), 10 μM acetaldehyde – 362 ± 72 (p = 0.0087 vs. vehicle). In contrast to ethanol and acetaldehyde, phosphatidylethanol did not affect the vasoconstrictor effects of PE (Fig 2E and 2F).

The effects of ethanol on aVP-induced constriction of mesenteric resistance arteries are shown in Fig 3A. As in Fig 1A–1C, arteries were pre-incubated with ethanol for 30 min, followed by stimulation with aVP; ethanol concentrations in the vessel bath were not kept constant. With increasing concentrations of ethanol, the aVP dose-response curves shifted slightly to the left (Fig 3A). As observed for PE-induced vasoconstriction, maximal aVP-induced vasoconstriction and Hill-slopes of the aVP dose-response curves were not altered after pre-incubation of the arteries with ethanol. Ethanol, however, significantly reduced the EC$_{50}$ concentration for the vasoconstrictor effects of aVP in a dose-dependent manner (Fig 3B). As compared with arteries that were not exposed to ethanol, pre-treatment of arteries with a starting concentration of 100 mM of ethanol increased the potency of aVP to induce vasoconstriction 1.7-fold (EC$_{50}$ (nM,
mean ± SEM): vehicle – 124 ± 14; 17.4 mM ethanol – 131 ± 20; 50 mM – 96 ± 11; 100 mM – 72 ± 9 (p = 0.049 vs. vehicle). In contrast to ethanol pre-treatment, pre-treatment of arteries with 10 μM of acetaldehyde or 2.1 μM of phosphatidylethanol did not affect the vasoconstrictor responses upon stimulation with aVP (Fig 3C). When tested at the highest concentrations that were used for PE- and aVP-dose response curves, ethanol, acetaldehyde and phosphatidylethanol did not affect constriction of mesenteric arteries upon stimulation with endothelin-1 (Fig 3D) or potassium chloride (Fig 3E). Furthermore, ethanol, acetaldehyde and phosphatidylethanol did not influence myogenic tone of the isolated arteries (Fig 3F).

Discussion

In the present study we utilized pressure myography as a test platform to evaluate direct effects of ethanol and ethanol metabolites on the intrinsic function of mesenteric resistance arteries. Utilizing this test platform for detailed dose-response experiments, we provide evidence that
ethanol selectively and dose-dependently sensitizes vasoconstriction upon activation of α₁-adrenergic and arginine vasopressin receptors. Furthermore, we show that the ethanol metabolite acetaldehyde also sensitizes vasoconstriction upon activation of α₁-adrenergic receptors but lacks effects on vasoconstriction upon activation of arginine vasopressin receptors. In contrast, the ethanol metabolite phosphatidylethanol did not affect intrinsic vasoconstrictor responses of isolated resistance arteries under our experimental conditions.

Acetaldehyde is produced through the enzymatic conversion of ethanol by alcohol dehydrogenase [28–33]. Acetaldehyde is a relatively short-lived metabolite which is further metabolized to acetate by acetaldehyde dehydrogenase [28, 30–34]. Multiple lines of evidence have previously suggested a role of acetaldehyde in the etiology of hypertension induced by ethanol consumption [35–41]. Phosphatidylethanol is the enzymatic product of the reaction of ethanol and phosphatidylcholine by phospholipase D [28, 42–46]. Phosphatidylethanol is of clinical interest as an alcohol consumption biomarker primarily due to its specificity and long biological half-life [28, 43–46]. The concentrations of ethanol and its metabolites that we used in the present study were selected to reflect clinically relevant blood ethanol concentrations and to include the ranges of blood acetaldehyde and phosphatidylethanol concentrations that have been observed in humans after ethanol consumption [46, 47].

Under our experimental conditions, ethanol evaporated from the vessel bath with a half-life of approximately 25 min. Thus, our findings indicate that a single and transient exposure of isolated arteries to ethanol is sufficient to sensitize intrinsic vascular function.

While ethanol dose-dependently sensitized vasoconstriction upon activation of the G protein-coupled α₁-adrenergic and vasopressin receptors, ethanol did not influence vasoconstriction via activation of voltage-operated Ca²⁺ channels by KCl, vasoconstriction mediated through the G protein-coupled endothelin receptor or myogenic tone. Thus, our findings document selectivity of the observed effects of ethanol on intrinsic vascular function. Similarly, the findings that acetaldehyde also sensitized PE-induced vasoconstriction but did not affect vasoconstriction induced by other vasopressors, suggest selectivity of its sensitizing actions.

Although many pharmacological actions of ethanol are attributed to indirect effects related to its metabolites, its effects on metabolism and on the central nervous system, evidence suggests that ethanol can also directly bind to ethanol binding sites or pockets on proteins, through which it affects protein function [48, 49]. For example, ethanol binding has been reported for nicotinic acetylcholine receptors, N-methyl-d-aspartate receptors or G protein-gated inwardly rectifying potassium channels, and mutational analyses suggest that ethanol modulates γ-aminobutyric acid type A ρ1 receptor through binding to specific binding sites located in the 2nd transmembrane domain of the receptor [48, 50–54]. Similarly, acetaldehyde is known to form stable and unstable adducts with proteins in vivo [55, 56]. The dose-effect profiles of ethanol and acetaldehyde that we observed in the present study indicate that their sensitizing effects on intrinsic vascular function are rapid, saturable and occur at clinically relevant concentrations, which could be consistent with direct binding of ethanol and acetaldehyde to the vasopressor receptors. The identification of possible receptor binding sites for ethanol and acetaldehyde, however, would require detailed structure-guided mutational analyses of possible binding sites. As such experiments are beyond the scope of the present study, the exact molecular mechanisms underlying the sensitizing effects of ethanol and acetaldehyde on intrinsic vascular function remain to be determined in the future.

It has been shown previously that acetaldehyde-induced hypertension in pithed rats can be attenuated with the α₁-adrenergic receptor antagonists phentolamine and prazosin and by pre-treatment of animals with reserpine, a catecholamine-depleting sympatholytic [40]. These data have previously been interpreted to reflect acetaldehyde-induced release of catecholamines as a mechanism through which acetaldehyde induces vasoconstriction and
hypertension in pithed rats [40]. The findings from the present study suggest that direct sensitizing effects of acetaldehyde on intrinsic vascular responsiveness to \(\alpha_1\)-adrenergic receptor activation likely contributed to these effects.

Previously, acetaldehyde concentrations of 1.9, 4.3 and 14 \(\mu\)M have been measured at blood ethanol concentrations of 17.1, 34.8 and 103.5 mM, respectively, one hour after ethanol gavage in rodents [57]. Thus, the dose-effect relationships for ethanol- and acetaldehyde-induced sensitization of \(\alpha_1\)-adrenergic receptor-mediated vasoconstriction that we observed in the present study match well with the relationship between ethanol and acetaldehyde concentrations in vivo [57]. Furthermore, 50% of east Asian populations exhibit an accumulation of acetaldehyde due to a variant of the ALDH2 gene, rs671 [29–34]. Our findings could provide a mechanism for the previously described relationship between increased acetaldehyde blood concentrations associated with the rs671 variant and an increased risk for the development of hypertension [30–34].

The effects of ex vivo exposure of mesenteric resistance arteries to ethanol on intrinsic vascular function that we observed in the present study resemble some but not all effects of ethanol consumption on intrinsic vascular function that have been observed previously [2, 6, 7, 21, 22, 58]. While differences between individual vascular beds, i.e. between mesenteric arteries, carotid arteries and the aorta, could account for such discrepancies, methodological differences in the assessment of intrinsic vascular function may also contribute. To the best of our knowledge, the majority of previous studies utilized wire myography to study the effects of ethanol consumption on intrinsic vascular function. While wire myography measures tension under isometric conditions and is prone to endothelial injury and non-physiological geometry and loading [59], pressure myography, which we employed in the present study, permits direct observation of vasoconstriction under isobaric conditions. Furthermore, our findings suggest that ethanol consumption resulting in blood ethanol concentrations above 17.4 mM leads to blood acetaldehyde concentrations that also sensitize intrinsic vascular function. Thus, it is conceivable that the parallel exposure of resistance arteries to ethanol, acetaldehyde and possibly other ethanol metabolites, such as fatty acid methyl esters, after ethanol consumption results in additional effects on intrinsic vascular function, beyond the effects of each molecule alone.

In the present study, however, we have limited our experiments to the study of the pharmacological effects of ethanol, acetaldehyde and phosphatidylethanol alone on intrinsic vascular function upon exposure to a single vasopressor. We abstained from combinatorial experiments to fully mimic in vivo conditions after ethanol consumption as such studies would not only require the exposure of mesenteric resistance arteries to various combinations of ethanol, acetaldehyde and other ethanol metabolites, but also to combinations of vasopressors. Such extensive studies, however, are technically not feasible within reasonable time frames and the interpretation of dose-response curves from such complex combination experiments appears daunting, if not impossible. Furthermore, we believe that the information gained from such experiments would only incrementally advance the key finding of the present study that ethanol and acetaldehyde have direct and selective effects on intrinsic vascular function.

Taken together, our findings demonstrate that ethanol and acetaldehyde selectively sensitize intrinsic constrictor responses of mesenteric resistance arteries upon activation of vascular \(\alpha_1\)-adrenergic and/or vasopressin receptors at clinically relevant concentrations. While the precise molecular mechanisms underlying their pharmacological effects remain to be determined, our findings further support the concept that enhanced vasoreactivity to endogenous vasoactive hormones contributes to the development of hypertension induced by ethanol consumption. Ex vivo exposure of mesenteric resistance arteries in pressure myography experiments resembles important aspects of vascular alterations that have been observed after
ethanol consumption, and thus could serve as a simple test platform to evaluate therapeutic interventions that are aimed to mitigate vascular effects of ethanol and acetaldehyde.

**Supporting information**

S1 Datasets. All data sets are provided in this file.

(XLSX)

**Acknowledgments**

Research reported in this publication was supported by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under award numbers R21AA025750 and T32AA013527. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Author Contributions**

**Conceptualization:** Matthias Majetschak.

**Formal analysis:** Jonathan M. Eby, Matthias Majetschak.

**Funding acquisition:** Matthias Majetschak.

**Investigation:** Jonathan M. Eby.

**Methodology:** Jonathan M. Eby, Matthias Majetschak.

**Project administration:** Matthias Majetschak.

**Resources:** Matthias Majetschak.

**Supervision:** Matthias Majetschak.

**Writing – original draft:** Matthias Majetschak.

**Writing – review & editing:** Jonathan M. Eby, Matthias Majetschak.

**References**

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015; 131(4):e29–322. https://doi.org/10.1161/CIR.0000000000000152 PMID: 25520374.

2. Marchi KC, Muniz JJ, Tirapelli CR. Hypertension and chronic ethanol consumption: What do we know after a century of study? World J Cardiol. 2014; 6(5):283–94. https://doi.org/10.4330/wjc.v6.i5.283 PMID: 24944758; PubMed Central PMCID: PMCPMC4062120.

3. Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010; 105(5):817–43. https://doi.org/10.1111/j.1360-0443.2010.02899.x PMID: 20331573; PubMed Central PMCID: PMCPMC3306013.

4. Fernandez-Sola J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol. 2015; 12(10):576–87. https://doi.org/10.1038/nrcardio.2015.91 PMID: 26099843.

5. Chan TC, Sutter MC. Ethanol consumption and blood pressure. Life Sci. 1983; 33(20):1965–73. PMID: 6685805.

6. Tirapelli CR, Leone AF, Coelho EB, Resstel LB, Correa FM, Lanchote VL, et al. Effect of ethanol consumption on blood pressure and rat mesenteric arterial bed, aorta and carotid responsiveness. J Pharm Pharmacol. 2007; 59(7):985–93. https://doi.org/10.1211/jpp.59.7.0011 PMID: 17637194.

7. Tirapelli CR, Leone AF, Yogi A, Tostes RC, Lanchote VL, Uyemura SA, et al. Ethanol consumption increases blood pressure and alters the responsiveness of the mesenteric vasculature in rats. J Pharm Pharmacol. 2008; 60(3):331–41. https://doi.org/10.1211/jpp.60.3.0008 PMID: 18264813.
8. Abdel-Rahman AA, Wooles WR. Ethanol-induced hypertension involves impairment of baroreceptors. Hypertension. 1987; 10(1):67–73. PMID: 3596770.

9. Vasdev S, Gupta IP, Sampson CA, Longerich L, Parai S. Ethanol induced hypertension in rats: reversibility and role of intracellular cytosolic calcium. Artery. 1993; 20(1):19–43. PMID: 8447725.

10. Utkan T, Yildiz F, Ilbay G, Ozdemirci S, Erden BF, Gacar N, et al. Blood pressure and vascular reactivity to endothelin-1, phenylephrine, serotonin, KCl and acetylcholine following chronic alcohol consumption in vitro. Fundam Clin Pharmacol. 2001; 15(3):157–65. PMID: 11468026.

11. Brown RA, Ilg KJ, Chen AF, Ren J. Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption. Eur J Pharmacol. 2002; 442(3):241–50. PMID: 12065078.

12. Reesiet LB, Tirapelli CR, Lanchote VL, Uyemura SA, de Oliveira AM, Coorema FM. Chronic alcohol consumption alters cardiovascular functions in conscious rats. Life Sci. 2006; 78(19):2179–87. https://doi.org/10.1016/j.lfs.2005.09.021 PMID: 16288925.

13. Rehm J, Shield KD, Roerecke M, Gmel G. Modelling the impact of alcohol consumption on cardiovascular disease mortality for comparative risk assessments: an overview. BMC public health. 2016; 16:363. Epub 2016/04/29. https://doi.org/10.1186/s12889-016-3026-9 PMID: 27121289; PubMed Central PMCID: PMCPMC4848866.

14. Mukamal KJ, Chen CM, Rao SR, Breslow RA. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol. 2010; 55(13):1328–35. https://doi.org/10.1016/j.jacc.2009.10.056 PMID: 20338493; PubMed Central PMCID: PMCPMC3865979.

15. Mathews JD. Alcohol usage as a possible explanation for socio-economic and occupational differentials in mortality from hypertension and coronary heart disease in England and Wales. Aust N Z J Med. 1976; 6(5):393–7. PMID: 1071866.

16. Husain K, Ansari RA, Farder L. Alcohol-induced hypertension: Mechanism and prevention. World J Cardiol. 2014; 6(5):245–52. https://doi.org/10.4330/wjc.v6.i5.245 PMID: 24891935; PubMed Central PMCID: PMCPMC4038773.

17. Grassi GM, Somers VK, Renk WS, Abboud FM, Mark AL. Effects of alcohol intake on blood pressure and sympathetic nerve activity in normotensive humans: a preliminary report. J Hypertens Suppl. 1989; 7(6):S20–1. PMID: 2632716.

18. Grassi GM, Somers VK, Renk WS, Abboud FM, Mark AL. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol. 2010; 55(13):1328–35. https://doi.org/10.1016/j.jacc.2009.10.056 PMID: 20338493; PubMed Central PMCID: PMCPMC3865979.

19. Rehm J, Shield KD, Roerecke M, Gmel G. Modelling the impact of alcohol consumption on cardiovascular disease mortality for comparative risk assessments: an overview. BMC public health. 2016; 16(1):363. https://doi.org/10.1186/s12889-016-3026-9 PMID: 27121289; PubMed Central PMCID: PMCPMC4848866.

20. Mathews JD. Alcohol usage as a possible explanation for socio-economic and occupational differentials in mortality from hypertension and coronary heart disease in England and Wales. Aust N Z J Med. 1976; 6(5):393–7. PMID: 1071866.

21. Altura BM, Altura BT. Peripheral and cerebrovascular actions of ethanol, acetaldehyde, and acetate: relationship to divalent cations. Alcohol Clin Exp Res. 1987; 11(2):99–111. Epub 1987/04/01. PMID: 3296839.

22. Crestani CC, Lopes da Silva A, Scopinho AA, Ruginsk SG, Uchoa ET, Correa FM, et al. Cardiovascular alterations at different stages of hypertension development during ethanol consumption: time-course of vascular and autonomic changes. Toxicology and applied pharmacology. 2014; 280(2):245–55. Epub 2014/08/26. https://doi.org/10.1016/j.taap.2014.08.012 PMID: 25151222.

23. Bach HH, Wong YM, Tripathi A, Nevis AM, Gamelli RL, Volkman BF, et al. Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular alpha1-adrenergic receptor function. Mol Med. 2014; 20:435–47. Epub 2014/07/18. https://doi.org/10.2119/molmed.2014.00101 PMID: 25032954; PubMed Central PMCID: PMCPMC4210213.

24. Evans AE, Vana PG, LaPorte HM, Kennedy RH, Gamelli RL, Majetschak M. Cardiovascular Responsiveness to Vasopressin and alpha1-Adrenergic Receptor Agonists After Burn Injury. J Burn Care Res. 2017; 38(2):90–8. Epub 2017/01/04. https://doi.org/10.1097/BCR.0000000000000374 PMID: 28045780; PubMed Central PMCID: PMCPMC5332293.

25. Evans AE, Tripathi A, LaPorte HM, Brueggemann LI, Singh AK, Albee LJ, et al. New Insights into Mechanisms and Functions of Chemokine (C-X-C Motif) Receptor 4 Heteromerization in Vascular Smooth Muscle. Int J Mol Sci. 2016; 17(5). Epub 2016/06/23. https://doi.org/10.3390/ijms17060971 PMID: 27331810; PubMed Central PMCID: PMCPMC4926503.
26. Albee LJ, Eby JM, Tripathi A, LaPorte HM, Gao X, Volkan BF, et al. alpha1-Adrenergic Receptors Function Within Hetero-Oligomeric Complexes With Atypical Chemokine Receptor 3 and Chemokine (C-X-C motif) Receptor 4 in Vascular Smooth Muscle Cells. J Am Heart Assoc. 2017; 6(8). Epub 2017/ 09/02. https://doi.org/10.1161/JAHA.117.006575 PMID: 28986294; PubMed Central PMCID: PMCPMC5886474.

27. Albee LJ, LaPorte HM, Gao X, Eby JM, Cheng YH, Nevinis AM, et al. Identification and functional characterization of arginine vasopressor receptor 1A: atypical chemokine receptor 3 heteromers in vascular smooth muscle. Open Biol. 2018; 8(1). Epub 2018/02/02. https://doi.org/10.1098/rsob.170207 PMID: 29986406; PubMed Central PMCID: PMCPMC5795052.

28. Ingall GB. Alcohol biomarkers. Clinics in laboratory medicine. 2012; 32(3):391–406. Epub 2012/09/04. https://doi.org/10.1016/j.clml.2012.06.003 PMID: 22393298.

29. Eng MY, Laczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol research & health: the journal of the National Institute on Alcohol Abuse and Alcoholism. 2007; 30(1):22–7. Epub 2007/08/28. PMID: 17718397; PubMed Central PMCID: PMCPMC3860439.

30. Ma C, Yu B, Zhang W, Wang W, Zhang L, Zeng Q. Associations between aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphisms, lifestyles and hypertension risk in Chinese Han people. Scientific reports. 2017; 7(1):11136. Epub 2017/09/13. https://doi.org/10.1038/s41598-017-11071-w PMID: 28894224; PubMed Central PMCID: PMCPMC5598392.

31. Chang YC, Chiu YF, Lee IT, Ho LT, Hung YJ, Hsiung CA, et al. Common ALDH2 genetic variants predict development of hypertension in the SAPPHIRe prospective cohort: gene-environmental interaction with alcohol consumption. BMC cardiovascular disorders. 2012; 12:58. Epub 2012/07/31. https://doi.org/10.1186/1471-2261-12-58 PMID: 22839215; PubMed Central PMCID: PMCPMC3476438.

32. Zhang WS, Xu L, Schooling CM, Jiang CQ, Chen XL, Mok DK, Lin ZX, et al. Meta-analysis of association between alcohol dehydrogenase 2 (ALDH2) rs671 genetic polymorphisms, lifestyles and hypertension risk in Asian populations. Herz. 2015; 40 Suppl (8):741–6. Epub 2013/04/26. https://doi.org/10.1038/hr.2013.23 PMID: 23615284; PubMed Central PMCID: PMCPMC3734527.

33. Zhang SY, Chan SW, Zhou X, Chen XL, Mok DK, Lin ZX, et al. Meta-analysis of association between ALDH2 rs671 polymorphism and essential hypertension in Asian populations. Herz. 2015; 40 Suppl 2:203–8. Epub 2014/11/19. https://doi.org/10.1007/s00059-014-4166-2 PMID: 25403981.

34. Pang J, Wang J, Zhang Y, Xu F, Chen Y. Targeting acetaldehyde dehydrogenase 2 (ALDH2) in heart failure—Recent insights and perspectives. Biochimica et biophysica acta. 2017; 1863(8):1933–41. Epub 2016/10/18. https://doi.org/10.1016/j.bbabio.2016.10.004 PMID: 27742538.

35. El-Mas MM, Abdel-Rahman AA. Enhanced catabolism to acetaldehyde in rostral ventrolateral medullary neurons accounts for the pressor effect of ethanol in spontaneously hypertensive rats. American journal of physiology Heart and circulatory physiology. 2012; 302(3):H837–44. Epub 2011/12/14. https://doi.org/10.1152/ajpheart.00958.2011 PMID: 22159996; PubMed Central PMCID: PMCPMC3353783.

36. El-Mas MM, Abdel-Rahman AA. Role of rostral ventrolateral medullary ERK/JNK/p38 MAPK signaling in the pressor effects of ethanol and its oxidative product acetaldehyde. Alcoholism, clinical and experimental research. 2013; 37(11):1827–37. Epub 2013/08/03. https://doi.org/10.1111/acer.12179 PMID: 23905689; PubMed Central PMCID: PMCPMC3812351.

37. Zhang X, Li SY, Brown RA, Ren J. Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad to ugly en route to oxidative stress. Alcohol (Fayetteville, NY). 2004; 32(3):175–86. Epub 2004/07/30. https://doi.org/10.1016/j.alcohol.2004.01.005 PMID: 15282111.

38. Green MA, Eggle JL Jr. The effects of acetaldehyde and acrolein on blood pressure in guanethidine-pre-treated hypertensive rats. Toxicology and applied pharmacology. 1983; 69(1):29–36. Epub 1983/06/15. PMID: 6857685.

39. Savage AO, Dunbar JC, Brown RA. Effects of acetaldehyde on the isolated papillary muscle of diabetic rats. Journal of cardiovascular pharmacology. 1995; 26(2):251–8. Epub 1995/08/01. PMID: 7475050.

40. Satoh Y, Ide Y, Sugano T, Koda K, Momose Y, Tagami M. Hypotensive and hypertensive effects of acetaldehyde on blood pressure in rats. Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence. 2008; 43(3):188–93. Epub 2008/07/24. PMID: 18646644.

41. Vasdev S, Mian T, Longering L, Prabhakaran V, Parai S. N-acetyl cysteine attenuates ethanol induced hypertension in rats. Artery. 1995; 21(6):312–6. PMID: 8833231.

42. Aroor AR, Shukla SD. MAP kinase signaling in diverse effects of ethanol. Life sciences. 2004; 74 (19):2339–44. Epub 2004/03/19. PMID: 15027449.

43. Andresen-Streichert H, Muller A, Glahn A, Skopp G, Sterneck M. Alcohol Biomarkers in Clinical and Forensic Contexts. Deutsches Arzteblatt international. 2018; 115(18):309–15. Epub 2018/05/29.
44. Stewart SH, Reuben A, Brzezinski WA, Koch DG, Basile J, Randall PK, et al. Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol and alcoholism (Oxford, Oxfordshire). 2009; 44(5):464–7. Epub 2009/06/19. https://doi.org/10.1093/alcalc/agp039 PMID: 19535495; PubMed Central PMCID: PMCPMC2765354.

45. Simon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regulatory toxicology and pharmacology; RTP. 2018; 94:163–71. Epub 2018/02/07. https://doi.org/10.1016/j.yrtph.2018.01.029 PMID: 29408287.

46. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol and alcoholism (Oxford, Oxfordshire). 2006; 41(4):431–7. Epub 2006/04/21. https://doi.org/10.1093/alcalc/agl027 PMID: 16624837.

47. Jones AW, Neiman J, Hillbom M. Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. Br J Clin Pharmacol. 1988; 25(2):213–21. PMID: 3358883; PubMed Central PMCID: PMCPMC1386476.

48. Khristalev VV, Khristaleva TA, Lelevich SV. Ethanol binding sites on proteins. J Mol Graph Model. 2017; 78:187–94. Epub 2017/10/28. https://doi.org/10.1016/j.jmgm.2017.10.017 PMID: 29078103.

49. Dwyer DS, Bradley RJ. Chemical properties of alcohols and their protein binding sites. Cell Mol Life Sci. 2000; 57(2):265–75. https://doi.org/10.1007/PL00000689 PMID: 10766022.

50. Borghese CM, Ruiz Cl, Lee US, Cullins MA, Bertaccini EJ, Trudell JR, et al. Identification of an Inhibitory Alcohol Binding Site in GABAA rho1 Receptors. ACS Chem Neurosci. 2016; 7(1):100–8. Epub 2015/11/17. https://doi.org/10.1021/acschemneuro.5b00246 PMID: 26571107; PubMed Central PMCID: PMCPMC4934417.

51. Blednov YA, Borghese CM, Ruiz Cl, Cullins MA, Da Costa A, Osterndorff-Kahanek EA, et al. Mutation of the inhibitory ethanol site in GABAA rho1 receptors promotes tolerance to ethanol-induced motor incoordination. Neuropharmacology. 2017; 123:201–9. Epub 2017/06/18. https://doi.org/10.1016/j.neuropharm.2017.06.013 PMID: 28623169; PubMed Central PMCID: PMCPMC5543808.

52. Davis TJ, de Fiebre CM. Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health. 2006; 29(3):179–85. Epub 2007/03/22. PMID: 17373406.

53. Ren H, Zhao Y, Wu M, Dwyer DS, Peoples RW. Two adjacent phenylalanines in the NMDA receptor GluN2A subunit M3 domain interactively regulate alcohol sensitivity and ion channel gating. Neuropharmacology. 2017; 114:20–33. Epub 2016/11/24. https://doi.org/10.1016/j.neuropharm.2016.11.013 PMID: 27876530; PubMed Central PMCID: PMCPMC5240780.

54. Glaaser IW, Siesinger PA. Dual activation of neuronal G protein-gated inwardly rectifying potassium (GIRK) channels by cholesterol and alcohol. Scientific reports. 2017; 7(1):4592. Epub 2017/07/06. https://doi.org/10.1038/s41598-017-04681-x PMID: 28676630; PubMed Central PMCID: PMCPMC5496853.

55. Niemela O. Acetaldehyde adducts in circulation. Novartis Found Symp. 2007; 285:183–92; discussion 93–7. Epub 2007/06/27. PMID: 17590995.

56. Turna DJ, Hoffman T, Sorrell MF. The chemistry of acetaldehyde-protein adducts. Alcohol Alcohol Suppl. 1991; 1:271–6. Epub 1991/01/01. PMID: 1845549.

57. Isse T, Matsuno K, Oyama T, Kitagawa K, Kawamoto T. Aldehyde dehydrogenase 2 gene targeting mouse lacking enzyme activity shows high acetaldehyde level in blood, brain, and liver after ethanol gavages. Alcohol Clin Exp Res. 2005; 29(11):1959–64. Epub 2005/12/13. PMID: 16340452.

58. Tirapelli CR, Casolari DA, Montezano AC, Yogi A, Tostes RC, Legros E, et al. Ethanol consumption enhances endothelin-1-induced contraction in the isolated rat carotid. J Pharmacol Exp Ther. 2006; 318(2):819–27. Epub 2006/05/03. https://doi.org/10.1124/jpet.106.103010 PMID: 16651399.

59. Lu X, Kassab GS. Assessment of endothelial function of large, medium, and small vessels: a unified myograph. Am J Physiol Heart Circ Physiol. 2011; 300(1):H94–H100. Epub 2010/11/16. https://doi.org/10.1152/ajpheart.00708.2010 PMID: 21076029; PubMed Central PMCID: PMCPMC3023250.